Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 20.78
-0.12 (-0.57%)
Feb 13, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,342 | 1,376 | 1,284 | 3,565 | 1,865 | 1,559 |
Other Revenue | 2.31 | 2.31 | 2.41 | 3.81 | 3.78 | 5.45 |
| 1,344 | 1,378 | 1,286 | 3,569 | 1,869 | 1,564 | |
Revenue Growth (YoY) | -4.15% | 7.15% | -63.97% | 91.00% | 19.44% | 482.93% |
Cost of Revenue | 436.35 | 437.47 | 514.89 | 1,393 | 389.97 | 182.96 |
Gross Profit | 908.04 | 940.43 | 771.1 | 2,176 | 1,479 | 1,381 |
Selling, General & Admin | 739.13 | 722.83 | 708.87 | 818.98 | 499.3 | 279.5 |
Research & Development | 288.37 | 300.39 | 338.62 | 396.11 | 230.32 | 125.53 |
Other Operating Expenses | -2.46 | 9.8 | 2.42 | 19.28 | 7.05 | 11.06 |
Operating Expenses | 1,037 | 1,053 | 1,043 | 1,326 | 748.74 | 426.56 |
Operating Income | -128.57 | -112.85 | -271.53 | 850.23 | 729.91 | 954.93 |
Interest Expense | -23.32 | -27.25 | -35.07 | -12.48 | -3.86 | -1.03 |
Interest & Investment Income | 18.33 | 22.73 | 60.24 | 65.42 | 27.15 | 13.09 |
Currency Exchange Gain (Loss) | -1.99 | -1.99 | 3.18 | 5.04 | -2.32 | -3.9 |
Other Non Operating Income (Expenses) | -6.14 | -7.52 | -3.91 | -45.03 | -0.88 | -0.52 |
EBT Excluding Unusual Items | -141.68 | -126.88 | -247.09 | 863.18 | 750 | 962.57 |
Gain (Loss) on Sale of Investments | 55.27 | 55.36 | 43.04 | 45.9 | 5.83 | 2.51 |
Gain (Loss) on Sale of Assets | 0.22 | -2.1 | 5.67 | -0.64 | -2.34 | -1.76 |
Asset Writedown | 1.31 | -1.8 | -1.73 | -204.23 | - | - |
Other Unusual Items | 18.3 | 17.16 | 84.39 | -94.82 | 10.96 | -4.07 |
Pretax Income | -66.58 | -58.25 | -115.71 | 609.39 | 764.45 | 959.26 |
Income Tax Expense | -33.66 | -38.63 | -42.85 | 15.88 | 86.16 | 137.53 |
Earnings From Continuing Operations | -32.92 | -19.62 | -72.86 | 593.51 | 678.29 | 821.73 |
Minority Interest in Earnings | 3.29 | 1.53 | 1.91 | 0.74 | - | - |
Net Income | -29.64 | -18.09 | -70.96 | 594.25 | 678.29 | 821.73 |
Net Income to Common | -29.64 | -18.09 | -70.96 | 594.25 | 678.29 | 821.73 |
Net Income Growth | - | - | - | -12.39% | -17.46% | 3085.62% |
Shares Outstanding (Basic) | 338 | 362 | 394 | 399 | 363 | 356 |
Shares Outstanding (Diluted) | 338 | 362 | 394 | 399 | 363 | 356 |
Shares Change (YoY) | -7.51% | -8.20% | -1.16% | 9.95% | 1.97% | - |
EPS (Basic) | -0.09 | -0.05 | -0.18 | 1.49 | 1.87 | 2.31 |
EPS (Diluted) | -0.09 | -0.05 | -0.18 | 1.49 | 1.87 | 2.31 |
EPS Growth | - | - | - | -20.32% | -19.05% | - |
Free Cash Flow | 114.14 | -84.58 | -79.91 | -227.69 | 354.84 | 651.01 |
Free Cash Flow Per Share | 0.34 | -0.23 | -0.20 | -0.57 | 0.98 | 1.83 |
Dividend Per Share | 0.150 | 0.180 | 0.100 | 1.250 | 0.300 | - |
Dividend Growth | 15.38% | 80.00% | -92.00% | 316.67% | - | - |
Gross Margin | 67.54% | 68.25% | 59.96% | 60.98% | 79.13% | 88.31% |
Operating Margin | -9.56% | -8.19% | -21.12% | 23.82% | 39.06% | 61.04% |
Profit Margin | -2.20% | -1.31% | -5.52% | 16.65% | 36.30% | 52.52% |
Free Cash Flow Margin | 8.49% | -6.14% | -6.21% | -6.38% | 18.99% | 41.61% |
EBITDA | -34.78 | -17.4 | -173.87 | 913.6 | 761.17 | 968.66 |
EBITDA Margin | -2.59% | -1.26% | -13.52% | 25.60% | 40.73% | 61.92% |
D&A For EBITDA | 93.79 | 95.45 | 97.66 | 63.37 | 31.26 | 13.73 |
EBIT | -128.57 | -112.85 | -271.53 | 850.23 | 729.91 | 954.93 |
EBIT Margin | -9.56% | -8.19% | -21.11% | 23.82% | 39.06% | 61.04% |
Effective Tax Rate | - | - | - | 2.61% | 11.27% | 14.34% |
Revenue as Reported | 1,344 | 1,378 | 1,286 | 3,569 | 1,869 | 1,564 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.